Evidence map›Paper›PMID 42781193›Full record

ReviewResearch (Washington, D.C.)2026

Benign Uroandrological Ecosystem: A Thorough Overview from Single-Cell and Spatial Transcriptomics.

Yandong Xie, Junjiang Ye, Jie Wang, Zhouting Tuo, Ruicheng Wu, Dilinaer Wusiman, William C Cho, Zhaojie Lyu, Qi Zhang, Dechao Feng and 1 more

Abstract readReview
In one paragraph

Review in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yandong XieUrology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.
Junjiang YeUrology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.ORCID https://orcid.org/0009-0000-3020-5996
Jie WangUrology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.
Zhouting TuoDepartment of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin, China.
Ruicheng WuUrology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.
Dilinaer WusimanPurdue Institute for Cancer Research, Purdue University, West Lafayette, IN 47907, USA.
William C ChoDepartment of Clinical Oncology, Queen Elizabeth Hospital, Hongkong SAR, China.
Zhaojie LyuDepartment of Urology, Institute of Precision Medicine, Shenzhen Key Laboratory of Male Reproduction and Genetics, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong, China.
Qi ZhangUrology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.
Dechao FengUrology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.ORCID https://orcid.org/57192943181
Dahong ZhangUrology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benign urological and andrological diseases (BUADs) represent common yet complex clinical challenges, where the diversity and dynamic nature of their microenvironments substantially influence disease onset and progression. In recent years, the emergence of single-cell RNA sequencing (scRNA-seq) and spatially resolved transcriptomic (SRT) technologies has provided unprecedented insights into the cellular heterogeneity and spatiotemporal architecture of these disease microenvironments. This review outlines current applications of scRNA-seq and SRT in BUADs, with a focus on their utility in mapping cell-cell interactions, uncovering pathological mechanisms, and prioritizing therapeutic targets. Across the upper urinary tract, prostate, bladder, urethra, and male reproductive organs, single-cell analyses reveal that parenchymal cell dysfunction and microenvironmental remodeling are the core pathological processes of disease progression. This review also discusses the limitations of scRNA-seq/SRT and the existing challenges of current research methods and paradigms in BUADs and outlines future research directions and integrative strategies to facilitate clinical translation and precision medicine. Collectively, these up-to-date findings not only deepen the understanding of the microenvironment in BUADs but also provide a scientific foundation for the development of novel therapeutic strategies.

Identifiers

PMID42781193
PMCPMC13598363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.